RLYB Projected Dividend Yield
Rallybio Corp ( NASDAQ : RLYB )Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Co.'s most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare hematological disease that impacts fetuses and newborns. Co. is evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase 1/2 clinical trial; and RLYB116, a subcutaneously administered inhibitor of complement factor 5. 20 YEAR PERFORMANCE RESULTS |
RLYB Dividend History Detail RLYB Dividend News RLYB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |